PubRank

Laurence Meyer

Author PubWeight™ 165.90‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013 6.14
2 The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010 5.85
3 When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011 5.35
4 On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med 2015 4.26
5 HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005 3.77
6 Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005 3.52
7 The UCSC Cancer Genomics Browser: update 2011. Nucleic Acids Res 2010 3.37
8 Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012 3.12
9 Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis 2010 3.01
10 Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis 2011 2.30
11 Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One 2008 2.14
12 CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006 2.02
13 CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol 2004 1.93
14 Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS 2003 1.81
15 Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 2002 1.79
16 Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol 2005 1.77
17 Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 2005 1.75
18 Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis 2011 1.68
19 Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? Clin Infect Dis 2005 1.64
20 Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 2005 1.64
21 French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005 1.63
22 Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology 2009 1.58
23 Exhaustive genotyping of the interleukin-1 family genes and associations with AIDS progression in a French cohort. J Infect Dis 2006 1.54
24 Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis 2005 1.54
25 CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med 2012 1.54
26 Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis 2011 1.50
27 HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006 1.45
28 Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS 2005 1.42
29 A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. Immunity 2013 1.41
30 Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One 2012 1.39
31 Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol 2008 1.35
32 Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis 2009 1.35
33 Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog 2013 1.33
34 Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004 1.31
35 Elevated IP10 levels are associated with immune activation and low CD4⁺ T-cell counts in HIV controller patients. AIDS 2014 1.28
36 Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis 2003 1.27
37 The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006 1.27
38 Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis 2012 1.25
39 Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis 2014 1.25
40 HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 2011 1.25
41 The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog 2013 1.24
42 Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 2003 1.24
43 HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 2012 1.23
44 Increase in at-risk sexual behaviour among HIV-1-infected patients followed in the French PRIMO cohort. AIDS 2002 1.20
45 CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS One 2011 1.20
46 Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One 2012 1.13
47 Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology 2012 1.13
48 Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010 1.12
49 The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS 2012 1.11
50 Recent HIV-1 infection contributes to the viral diffusion over the French territory with a recent increasing frequency. PLoS One 2012 1.11
51 Early control of HIV-1 infection in long-term nonprogressors followed since diagnosis in the ANRS SEROCO/HEMOCO cohort. J Acquir Immune Defic Syndr 2009 1.08
52 Influence of CD4 cell counts on the genetic heterogeneity of hepatitis C virus in patients coinfected with human immunodeficiency virus. J Infect Dis 2002 1.07
53 High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother 2009 1.07
54 IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007 1.07
55 The HIV RNA setpoint theory revisited. Retrovirology 2007 1.06
56 No evidence of a change in HIV-1 virulence since 1996 in France. AIDS 2009 1.05
57 Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts). J Acquir Immune Defic Syndr 2008 1.04
58 Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009 1.04
59 Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther 2007 1.04
60 Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. J Antimicrob Chemother 2010 1.03
61 Natural history of HIV-control since seroconversion. AIDS 2013 1.02
62 Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. Clin Infect Dis 2012 1.02
63 Biomarker-based HIV incidence in a community sample of men who have sex with men in Paris, France. PLoS One 2012 0.99
64 Employment loss following HIV infection in the era of highly active antiretroviral therapies. Eur J Public Health 2005 0.99
65 Evidence for a key role of steroids in the modulation of pain. Psychoneuroendocrinology 2009 0.99
66 Level of double negative T cells, which produce TGF-β and IL-10, predicts CD8 T-cell activation in primary HIV-1 infection. AIDS 2012 0.99
67 Protective effect of interleukin-4 -589T polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load. J Infect Dis 2002 0.97
68 Pivotal role of M-DC8⁺ monocytes from viremic HIV-infected patients in TNFα overproduction in response to microbial products. Blood 2012 0.97
69 Progress in dorsal root ganglion neurosteroidogenic activity: basic evidence and pathophysiological correlation. Prog Neurobiol 2010 0.96
70 HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. J Clin Virol 2008 0.96
71 Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use. AIDS 2012 0.95
72 New and old complex recombinant HIV-1 strains among patients with primary infection in 1996-2006 in France: the French ANRS CO06 primo cohort study. Retrovirology 2008 0.93
73 Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers. J Virol 2013 0.93
74 A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLoS One 2013 0.92
75 Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort. Antivir Ther 2012 0.92
76 Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology 2013 0.92
77 Yearly number of patients diagnosed with primary HIV-1 infection in France estimated by a capture-recapture approach. AIDS 2006 0.92
78 Sciatic nerve injury induces apoptosis of dorsal root ganglion satellite glial cells and selectively modifies neurosteroidogenesis in sensory neurons. Glia 2010 0.92
79 Biochemical and functional evidence for the control of pain mechanisms by dehydroepiandrosterone endogenously synthesized in the spinal cord. FASEB J 2007 0.92
80 Temporary employment, absence of stable partnership, and risk of hospitalization or death during the course of HIV infection. J Acquir Immune Defic Syndr 2005 0.89
81 Circulation of multiple patterns of unique recombinant forms B/CRF02_AG in France: precursor signs of the emergence of an upcoming CRF B/02. AIDS 2011 0.89
82 Causal pathways of the effects of age and the CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on AIDS development. J Acquir Immune Defic Syndr 2005 0.88
83 Comparison of early CD4 T-cell count in HIV-1 seroconverters in Côte d'Ivoire and France: the ANRS PRIMO-CI and SEROCO cohorts. J Acquir Immune Defic Syndr 2010 0.88
84 Neurogenic pain and steroid synthesis in the spinal cord. J Mol Neurosci 2006 0.87
85 Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection. J Clin Microbiol 2010 0.86
86 Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells. AIDS 2009 0.85
87 Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+ CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection. Blood 2008 0.85
88 Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. J Infect Dis 2012 0.84
89 Performance of an immunoassay at detecting recent infection among reported HIV diagnoses. AIDS 2009 0.84
90 IL-23 and IL-12p70 production by monocytes and dendritic cells in primary HIV-1 infection. J Leukoc Biol 2010 0.84
91 Characterization of an old complex circulating recombinant form, CRF27_cpx, originating from the Democratic Republic of Congo (DRC) and circulating in France. AIDS Res Hum Retroviruses 2008 0.84
92 CD8 T-cells from most HIV-infected patients lack ex vivo HIV-suppressive capacity during acute and early infection. PLoS One 2013 0.84
93 Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration. PLoS One 2013 0.83
94 Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic. PLoS Pathog 2013 0.83
95 Sexually-transmitted/founder HIV-1 cannot be directly predicted from plasma or PBMC-derived viral quasispecies in the transmitting partner. PLoS One 2013 0.83
96 Long-term nonprogression of HIV infection in children: evaluation of the ANRS prospective French Pediatric Cohort. Clin Infect Dis 2007 0.83
97 Trends in unsafe sex and influence of viral load among patients followed since primary HIV infection, 2000-2009. AIDS 2011 0.83
98 Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. Clin Infect Dis 2015 0.83
99 HIV-1 co-infection prevalence in two cohorts of early HIV-1 seroconverters in France. AIDS 2007 0.83
100 Deleterious genetic influence of CX3CR1 genotypes on HIV-1 disease progression. J Acquir Immune Defic Syndr 2003 0.82
101 Assessment of the diagnostic sensitivity and specificity of an indirect ELISA kit for the diagnosis of Brucella ovis infection in rams. BMC Vet Res 2012 0.82
102 Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy. AIDS 2015 0.81
103 Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. J Acquir Immune Defic Syndr 2012 0.81
104 Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naive HIV-infected persons: the ANRS CO9 «COPANA» cohort study. PLoS One 2013 0.81
105 Dose-dependent and sequence-sensitive effects of amyloid-beta peptide on neurosteroidogenesis in human neuroblastoma cells. Neurochem Int 2008 0.81
106 Estimation of sensitivity and specificity of five serological tests for the diagnosis of porcine brucellosis. Prev Vet Med 2011 0.81
107 Progeny's mental aptitudes in man: relationship with parental age at conception and with some environmental factors. C R Biol 2009 0.81
108 Short communication: evidence of HIV type 1 complex and second generation recombinant strains among patients infected in 1997-2007 in France: ANRS CO06 PRIMO Cohort. AIDS Res Hum Retroviruses 2010 0.81
109 MHC-driven HIV-1 control on the long run is not systematically determined at early times post-HIV-1 infection. AIDS 2013 0.81
110 Detecting spatial memory deficits beyond blindness in tg2576 Alzheimer mice. Neurobiol Aging 2012 0.81
111 Selective regulation of 3 alpha-hydroxysteroid oxido-reductase expression in dorsal root ganglion neurons: a possible mechanism to cope with peripheral nerve injury-induced chronic pain. Pain 2010 0.80
112 Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy. Arthritis Rheum 2007 0.79
113 Automated comparison of last hospital main diagnosis and underlying cause of death ICD10 codes, France, 2008-2009. BMC Med Inform Decis Mak 2014 0.79
114 Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies? AIDS 2014 0.79
115 Decreased specificity of an assay for recent infection in HIV-1-infected patients on highly active antiretroviral treatment: implications for incidence estimates. Clin Vaccine Immunol 2012 0.79
116 Thrombocytopenia during primary HIV-1 infection predicts the risk of recurrence during chronic infection. J Acquir Immune Defic Syndr 2012 0.78
117 When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. J Acquir Immune Defic Syndr 2016 0.78
118 Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts. PLoS One 2013 0.77
119 Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment. AIDS 2002 0.77
120 X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI. PLoS One 2011 0.77
121 Does pregnancy affect the early response to cART? AIDS 2013 0.77
122 Assessment of neuroactive steroid formation in diabetic rat spinal cord using high-performance liquid chromatography and continuous flow scintillation detection. Neurochem Int 2007 0.77
123 Regulatory effect of dehydroepiandrosterone on spinal cord nociceptive function. Front Biosci (Elite Ed) 2010 0.77
124 The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. AIDS 2016 0.77
125 Plasmacytoid dendritic cells and myeloid cells differently contribute to B-cell-activating factor belonging to the tumor necrosis factor superfamily overexpression during primary HIV infection. AIDS 2016 0.76
126 Neonatal ventral hippocampal lesions modify pain perception and evoked potentials in rats. Behav Brain Res 2012 0.76
127 Specific anti-gp41 antibodies predict HIV-1 disease progression. J Acquir Immune Defic Syndr 2012 0.76
128 Influence of the R22H variant of macrophage inflammatory protein 1beta/Lag-1 in HIV-1 survival. AIDS 2005 0.76
129 Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals. Medicine (Baltimore) 2016 0.75
130 Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion--reply. JAMA Intern Med 2013 0.75
131 MELD Score Kinetics in Decompensated HIV+/HCV+ Patients: A Useful Prognostic Tool (ANRS HC EP 25 PRETHEVIC Cohort Study). Medicine (Baltimore) 2015 0.75
132 Sub-Saharan Africa migrants have slower initial CD4 cell recovery after cART initiation than French natives, regardless of living conditions. AIDS 2017 0.75
133 First report of transmission of a highly resistant strain of HIV-1 group O. AIDS 2016 0.75
134 Undetectable HIV-1 RNA load with the Cobas TaqMan v1.0 in a patient diagnosed at the time of primary HIV-1 infection. J Med Virol 2010 0.75
135 Correction: Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. PLoS Biol 2017 0.75
136 Evaluation of five serological tests for the diagnosis of porcine brucellosis in French Polynesia. Trop Anim Health Prod 2012 0.75
137 Incidence and risk factors for recurrent sexually transmitted infections among men who have sex with men on HIV pre-exposure prophylaxis. AIDS 2022 0.75
138 Fever and lymphadenopathy in a farmer. Arch Dermatol 2004 0.75
139 Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naïve patients from the ANRS COPANA cohort. AIDS 2017 0.75
140 Testing independence between two sequential gap times in the presence of covariates. Biom J 2012 0.75
141 Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older. J Acquir Immune Defic Syndr 2017 0.75
142 [Why do women more often inform their sexual partners of a sexually transmitted infection? The clinicians' role]. Med Sci (Paris) 2008 0.75
143 Costs and benefits of On-Demand HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men Analysis of the ANRS IPERGAY study with a one-year follow-up. AIDS 2017 0.75
144 Steroids, spinal cord and pain sensation. Horm Mol Biol Clin Investig 2011 0.75
145 Sub-Saharan African migrants have slower initial CD4+ cell recovery after combined antiretroviral treatment initiation than French natives. AIDS 2017 0.75
146 Hospital comparisons based on mortality: revisiting the choice of postadmission timeframe and evaluating the contribution of cause-of-death data, France, 2009. Med Care 2015 0.75